الفهرس 
AcknowledgementOnly 14 pages are availabe for public view
 |  | from | 195 |  |  |
| | | from | 195 | | |
Abstract
HBV is the world’s most common blood-borne viral infection responsible for substantial morbidity and mortality in the human population, both from acute infection and chronic sequelae. It was estimated that as many as 300 million persons worldwide are chronically infected with HBV and are therefore at risk of developing chronic liver disease or hepatocellular carcinoma. The risk of occupationally acquired HBV infection has been well recognized. Frequent exposure to blood or other biological fluids in common among HCW who are thus at high risk of HB infection. Their risk has been estimated to be ten times that of the general population. With the availability of safe, immunogenic and protective HB vaccines , it should be possible to introduce effective vaccination programs for the prevention of HB infection. The Egyptian Medical Syndicate has provided HB vaccine since late 1991 . Doctors .~ being at particular risk were voluntarily vaccinated. The aim of the present study was to determine the efficacy of the current HB vaccine in induction of protective ImmUnIty against HBV among vaccinated doctors and to correlate the response to the vaccine with different factors. One hundred and eighty two vaccinated doctors of different specialities were included in this study. They worked in different hospitals in Alexandria. All doctors included had received the three intramuscular injections of HB vaccine (following the 0,1 and 6 month schedule) . Both sexes were included with a mean age 32.5 years. Relevant data were collected from each doctor including personal data (e.g age, sex, weight, height, speciality, cigarette smoking, .. etc) , health data (e.g history of jaundice, history of blood transfusion, .. etc ) an~ data related to vaccine administration ( e.g site of injection, time lapse after the third vaccine dose, reactions after vaccination, .. etc) . A blood sample was collected from each doctor one to 6 months after the third vaccine dose, and serum samples were. tested using the ELISA technique for the presence of anti-HBc to determine past exposure of doctors to HBV and the presence of anti-HBs with the dete’rmination of its level to evaluate